RE:RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024May 13, 2024 - Large-cap and specialty pharma companies are continuously hunting for targets, said Ali Pashazadeh, founder, chairman and CEO of the financial advisor Treehill Partners. Pharma companies often have internal programs already in place for most tumor types but will acquire where there is a “white space” in their pipeline, he added.
The landscape of oncology also has moved from monotherapy to combination therapy, with hundreds of combinations with immune checkpoint inhibitors in development, Pashazadeh said. At the same time, developing treatment combinations is “exponentially harder” than for monotherapies, Pashazadeh continued. “That being said, oncology remains one of the — if not the — most lucrative therapeutic areas for pharma and biotech companies.”